retatrutide approval fda 2025 is the most significant weight-loss pharmaceutical currently in clinical development. Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of 28.7% at 68 weeks — approaching outcomes Retatrutide is the most significant
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



























